Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
• Treatments: Methocarbamol

Criteria

Inclusion Criteria:

• Hospitalized for acute heart failure

• Dyspnea at rest or with minimal exertion

• Pulmonary congestion

• Able to provide informed consent

• Systolic blood pressure > 125 mmHg

• Impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2

Exclusion Criteria:

• Use of other IV therapies for acute heart failure

• Fever or sepsis

• Recent major neurologic event

• Recent major surgery

• Recent acute coronary syndrome

• Other recent investigational drug use